other material
confidence high
sentiment neutral
materiality 0.50
Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program
Xenon Pharmaceuticals Inc.
- Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.
- Prior ATM sales total $291,084,564 as of filing date; prior program terminated.
- Sales agents are Jefferies and Stifel; shares issuable under Sales Agreement dated Aug 2020 as amended.
- Registration statement automatically effective on Form S-3 filed Aug 2024.